ProCE Banner Activity

CE / CME

Expert Analysis of Key Studies at the 2024 ASCO Genitourinary Cancers Symposium

Conference Coverage
Text Module

Experts Dr Terence Friedlander and Dr Rana McKay present in-depth discussion and analysis of key studies presented at the 2024 ASCO Genitourinary Cancers Symposium.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: March 25, 2024

Expiration: March 24, 2025

Share

Faculty

Terence Friedlander

Terence Friedlander, MD

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Zuckerberg San Francsico General Hospital
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This program is intended for physicians, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with genitourinary cancers.

Program Learning Goal

This activity aims to improve learners’ knowledge and competence in optimally applying recent practice-changing findings in treating patients with genitourinary cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recently presented data, as appropriate and guided by expert recommendations, to optimize care for patients with genitourinary cancers

  • Distinguish subpopulations of genitourinary cancers patients most likely to benefit from specific treatment based on prognostic or predictive markers

  • Interpret new data on novel agents and therapeutic strategies for patients with genitourinary cancers to aid optimal integration into practice

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Terence Friedlander, MD

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Zuckerberg San Francsico General Hospital
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Terence Friedlander, MD: consultant/advisor/speaker: AADI Biosciences, Astellas, AstraZeneca, EMD Serono, Merck, Seagen.

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Rana R. McKay, MD, FASCO: consultant/advisor/speaker: Ambrx, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Eisai, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, CTI/SOBI, Daichii Sankyo, Lilly, Morphosys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 25, 2024, through March 24, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-085-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days. 

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until  March 24, 2025. PAs should only claim credit commensurate with the extent of their participation.